Founder Spotlight: Nate Wilbourne of Precision Genetics

A look inside how the thriving company brings patient-driven purpose to health care innovation

For CEO Nate WilbournePrecision Genetics isn’t just positioned for accelerated growth. He sees the potential for the company he founded in 2014 to positively impact personalized medicine far into the future.

“We started off as a molecular diagnostic solution,” Wilbourne says. “I saw a market opportunity to use technology to drive clinical utility at the physician level — genetic information is very valuable to doctors in treating their patients, as long as the information is given to them as actionable data. We set out to digitize that process, using molecular sciences to improve patient care, which ultimately drives better patient outcomes.”

As many entrepreneurs know, the initial vision can change once you start growing — and staying nimble is key.

“Over the years, things evolved, and we fine-tuned our model [during the pandemic]. We took a really niche focus that allowed the company to become a differentiated solution,” Wilbourne says. 

Beyond his business acumen, Wilbourne is passionate about the greater purpose in his work.

“For the most part, everyone will be sick or face a potentially life-threatening diagnosis at some point in life,” he says. “We want our doctors to treat us as individuals — we’re moving away from the days of blindly prescribing medications or treatment pathways based solely on population analytics. With genetic testing, we sequence your entire DNA infrastructure, and that acts as your offensive playbook [in care]. I’d love to see this become part of everyone’s personal health record. If we can do that, we really are changing the standard of care.”

With banking partners like Fifth-Third Bank, the growth trajectory for Precision Genetics appears exponential.

“I really enjoy working with [the team at Fifth-Third]; they’re very hands-on and make you feel like it’s a true banking relationship,” adds Wilbourne. “My goal is to create a substantial multiple for the company’s original investors, as well as potentially position this company to be acquired.”

Article originally printed in Upstate Business Journal – by: J. Morgan McCallum September 2, 2022